Handa Neuroscience

Handa Neuroscience is a U.S. specialty pharmaceutical subsidiary of Taiwan-based Handa Pharmaceuticals focused on neurology products. The company is best known as the owner and developer of TASCENSO ODT, an orally disintegrating fingolimod product for relapsing forms of multiple sclerosis. Handa Neuroscience appears to operate within the broader Handa group structure rather than as a stand-alone diversified biotech platform company. Its business model centers on developing and commercializing differentiated prescription medicines, particularly reformulated or specialty dosage forms, and partnering commercialization to companies such as Cycle Pharmaceuticals. Based on publicly available information, its visible pipeline is concentrated around TASCENSO ODT rather than a broad multi-asset neuroscience portfolio.